Drug Shortage Report for TEVA-CEPHALEXIN 250
Report ID | 173043 |
Drug Identification Number | 00342092 |
Brand name | TEVA-CEPHALEXIN 250 |
Common or Proper name | TEVA-CEPHALEXIN 250 |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | CEPHALEXIN |
Strength(s) | 250MG |
Dosage form(s) | POWDER FOR SUSPENSION |
Route of administration | ORAL ORAL |
Packaging size | 100,150ml |
ATC code | J01DB |
ATC description | OTHER BETA-LACTAM ANTIBACTERIALS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2022-10-28 |
Estimated end date | 2023-05-30 |
Actual end date | 2023-06-08 |
Shortage status | Resolved |
Updated date | 2024-02-14 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.